Iguana Healthcare Management LLC acquired a new stake in Voyager Therapeutics Inc (NASDAQ:VYGR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,000 shares of the company’s stock, valued at approximately $515,000. Iguana Healthcare Management LLC owned approximately 0.08% of Voyager Therapeutics as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Voyager Therapeutics during the second quarter valued at approximately $143,000. Rhumbline Advisers raised its position in Voyager Therapeutics by 34.7% during the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after purchasing an additional 4,144 shares during the period. Goldman Sachs Group Inc. raised its position in Voyager Therapeutics by 8.9% during the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after purchasing an additional 1,399 shares during the period. Finally, Teachers Advisors LLC raised its position in Voyager Therapeutics by 24.7% during the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after purchasing an additional 5,081 shares during the period. Institutional investors and hedge funds own 35.97% of the company’s stock.
Shares of Voyager Therapeutics Inc (NASDAQ VYGR) traded down $0.36 on Friday, reaching $16.60. The company’s stock had a trading volume of 288,807 shares, compared to its average volume of 396,763. Voyager Therapeutics Inc has a 12 month low of $8.10 and a 12 month high of $25.99. The firm has a market cap of $533.38, a P/E ratio of -5.85 and a beta of 3.90.
A number of research analysts have recently commented on VYGR shares. BTIG Research began coverage on Voyager Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $32.00 target price for the company. Piper Jaffray Companies restated an “overweight” rating and set a $28.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 28th. Wedbush reiterated an “outperform” rating and set a $26.00 price objective (up previously from $22.00) on shares of Voyager Therapeutics in a report on Monday, November 20th. Canaccord Genuity set a $26.00 price objective on Voyager Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.90.
ILLEGAL ACTIVITY NOTICE: “25,000 Shares in Voyager Therapeutics Inc (NASDAQ:VYGR) Acquired by Iguana Healthcare Management LLC” was first posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://weekherald.com/2017/12/30/iguana-healthcare-management-llc-acquires-shares-of-25000-voyager-therapeutics-inc-vygr.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.